Biotech Balancing Act Survey Insights and Expectations

Even with the macro-level obstacles, the biotech sector continues to grow across multiple metrics, with a backlog of emergent companies and R&D spend rising across the board. The end-toend capabilities, global presence, and wide service offering of larger CROs provide specialized biotech organizations with a level of continuity across their development program that ad hoc contracting doesn't, facilitating integrated access to the necessary operational excellence, resources, and capacity. OPTIMIZING R&D TOGETHER As R&D spend rises across the board, from large pharma to emerging biotech companies, optimization will be a continued focus into 2024 and beyond.